Literature DB >> 10353632

Involvement of diazepam binding inhibitor and its fragment octadecaneuropeptide in social isolation stress-induced decrease in pentobarbital sleep in mice.

E Dong1, K Matsumoto, M Tohda, H Watanabe.   

Abstract

Diazepam binding inhibitor (DBI) and its fragment, octadecaneuropeptide (ODN), are putative endogenous ligands for benzodiazepine (BZD) receptors and have been shown to act as an inverse BZD receptor agonist in the brain. A previous study suggested that the social isolation stress-induced decrease in pentobarbital sleep in mice was partly due to endogenous substances with an inverse BZD receptor agonist-like property. In this study, we examined the effects of DBI and ODN on pentobarbital sleep in group-housed and socially isolated mice to test the possible involvement of DBI and ODN in a social isolation-induced decrease in pentobarbital sleep. The socially isolated mice showed significantly shorter durations of pentobarbital (50 mg/kg, intraperitoneally, i. p.) sleep compared to the group-housed animals. When injected intracerebroventricularly (i.c.v.), DBI and ODN (3 and 10 nmol) dose-dependently shortened the pentobarbital-induced sleeping time in group-housed mice at the same dose range, but these peptides had no effect on the sleeping time in socially isolated animals. In contrast, flumazenil (16.5-33 nmol, i.c.v.), a BZD receptor antagonist, reversed the pentobarbital sleeping time in socially isolated mice to the level of group-housed animals without affecting the sleeping time in group-housed animals. The effects of DBI and ODN in group-housed mice were significantly blocked by flumazenil (33 nmol, i.c.v.). Moreover, the effect of flumazenil in socially isolated mice was significantly attenuated by DBI and ODN (10 nmol, i.c.v.). These results suggest that the changes in the activity of DBI and/or ODN are partly involved in the social isolation-induced decrease in the hypnotic action of pentobarbital in mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353632     DOI: 10.1016/s0024-3205(99)00116-2

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  A functional continuum of regulatory anxiety-enhancing peptides. The search for complexes providing the optimal basis for developing inhibitory therapeutic agents.

Authors:  S V Koroleva; I P Ashmarin
Journal:  Neurosci Behav Physiol       Date:  2006-02

2.  Activity-dependent expression of acyl-coenzyme a-binding protein in retinal muller glial cells evoked by optokinetic stimulation.

Authors:  Neal H Barmack; Timothy R Bilderback; Henry Liu; Zuyuan Qian; Vadim Yakhnitsa
Journal:  J Neurosci       Date:  2004-02-04       Impact factor: 6.167

3.  Endogenous positive allosteric modulation of GABA(A) receptors by diazepam binding inhibitor.

Authors:  Catherine A Christian; Anne G Herbert; Rebecca L Holt; Kathy Peng; Kyla D Sherwood; Susanne Pangratz-Fuehrer; Uwe Rudolph; John R Huguenard
Journal:  Neuron       Date:  2013-05-30       Impact factor: 17.173

Review 4.  Toward a neurology of loneliness.

Authors:  Stephanie Cacioppo; John P Capitanio; John T Cacioppo
Journal:  Psychol Bull       Date:  2014-09-15       Impact factor: 17.737

5.  The octadecaneuropeptide ODN protects astrocytes against hydrogen peroxide-induced apoptosis via a PKA/MAPK-dependent mechanism.

Authors:  Yosra Hamdi; Hadhemi Kaddour; David Vaudry; Seyma Bahdoudi; Salma Douiri; Jérôme Leprince; Helene Castel; Hubert Vaudry; Marie-Christine Tonon; Mohamed Amri; Olfa Masmoudi-Kouki
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

6.  The stimulatory effect of the octadecaneuropeptide ODN on astroglial antioxidant enzyme systems is mediated through a GPCR.

Authors:  Yosra Hamdi; Hadhemi Kaddour; David Vaudry; Salma Douiri; Seyma Bahdoudi; Jérôme Leprince; Hélène Castel; Hubert Vaudry; Mohamed Amri; Marie-Christine Tonon; Olfa Masmoudi-Kouki
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-21       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.